Interview with Marko Dolzan, President, Polfa Lodz
You were the CEO for three different companies and the founder of Sensilab and then you acquired Polfa Lodz. Could you relate to our readers the development of your career…
Address: ul. Drewnowska 43/55, 91-002 Lodz
Tel: +48 42 654 00 70
Web: http://www.polfa-lodz.com/
For 75 years, we have been specialising in producing top quality medicinal products, dietary supplements and cosmetics. Thanks to the trust of physicians and pharmacists, our products can be found in every Polish home.
Our strongest desire is to perfect our preparations and to make efforts to increase their safety and efficacy. We are constantly striving to maintain the highest production standards – our production processes comply with GMP, HACCP and ISO standards.
In order to maintain continuous development, we merged with SENSILAB Sp. z o.o. in 2008.
We are one of the leading drugs and dietary supplements manufacturers in Poland. Every year over 5,000,000 packets of our products are shipped to our customers. We offer over 50 different preparations. We are a leading manufacturer of calcium preparations based on the most easily absorbable form of calcium.
We are a pharmaceutical manufacturer which – apart from producing its own preparations – also provides contracted production services. Depending on the demand, our R&D department can develop products to be manufactured under a customer’s brand name. Owing to our modern and highly efficient equipment, we can fulfil your orders promptly. We take production services for our partners very seriously. We treat every enquiry on an individual basis, which results in the comprehensive service that our company can offer.
You were the CEO for three different companies and the founder of Sensilab and then you acquired Polfa Lodz. Could you relate to our readers the development of your career…
Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment…
Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She…
Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Witold Włodarczyk, director general of Polmed (Polish chamber for medical devices), discusses the Polish medical device landscape and the policy surrounding the sector, especially the proposed 2016 reimbursement act. Furthermore,…
Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore,…
Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better…
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments.…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
See our Cookie Privacy Policy Here